🔴 Cue Biopharma is trading 5.6% down in pre-market — no reliable overnight catalyst reported

Cue Biopharma is trading 5.55% down at $26.70, with no reliable overnight announcement explaining the additional pre-market decline.

• Shares fell 23.70% during the September 21 session.
• The September 20 announcement of positive Phase 2 CUE-221 results remains the latest confirmed company news, citing statistically significant efficacy and a favorable safety profile.
• Major U.S. indices are modestly higher, so broader market sentiment does not clearly account for the move.